CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 26 enrolled
Drug / intervention
Vitamin D (cholecalciferol)dietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01068418
NCT01068418N/ACompleted
CompareCT.gov

Vitamin D Deficiency Augments Renin-Angiotensin System Activity in Obesity

Brigham and Women's Hospital·interventional·Posted Feb 15, 2010·Updated Mar 30, 2017

In Brief

A clinical study evaluating Vitamin D (cholecalciferol) for Obesity and 2 related conditions. Completed, enrolled 26 participants across 1 site.

Detailed Summary

Hypothesis: Vitamin D supplementation lower renin-angiotensin system activity in obesity. Specific Aim: To investigate whether Vitamin D supplementation in obesity improves the vascular sensitivity to angiotensin II.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Vitamin D Deficiency, Hypertension
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 15, 2010
Enrollment StartFeb 1, 2010
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 16.4 years ago

Interventions

Vitamin D (cholecalciferol)dietary

cholecalciferol 15,000 IU daily for 30 days